A total of 82 clinical isolates of methicillin-resistant Staphylococcus aureus and 21 isolates of methicillin-susceptible S. aureus were studied for in vitro susceptibility to N-formimidoyl thienamycin at incubation temperatures of 30 and 35°C. The disk diffusion test results were correlated with the macrobroth dilution test by means of the error rate-bounded method of analysis. Both methicillin-susceptible and (to a lesser degree) methicillin-resistant strains were generally susceptible to the antibiotic as judged from their minimum inhibitory concentrations. The discrepancy between in vitro results obtained at 30 and at 35°C was not very remarkable. However, tolerance of N-formimidoyl thienamycin was observed in 37% of methicillin-resistant strains and 24% of methicillin-susceptible strains at an incubation temperature of 30°C; at 35°C, the values were 54% (methicillinresistant strains) and 14% (methicillin-susceptible strains).
Methicillin-resistant (MR) Staphylococcus aureus strains frequently demonstrate resistance to the older and newer cephalosporins (1, 6, 7) . Currently, vancomycin remains the only antibiotic to which the microorganisms are consistently susceptible (5) . Recently, however, a unique and novel P-lactam agent, N-formimidoyl thienamycin (N-F-thienamycin), has shown very promising in vitro activity against gram-positive cocci, including methicillin-susceptible (MS) S. aureus (9, 10, 13 according to previously published guidelines (3, 12) ( Fig. 1 and 2) . (6, 7) .
The clinical significance of the antibiotic tolerance to N-F-thienamycin observed with both MR and MS S. aureus is unclear. Further studies should be done to determine whether adding a second antibiotic will abolish this in vitro tolerance. 
